MANNKIND CORP Liabilities Assumed
MANNKIND CORP (MNKD) reported Liabilities Assumed of $1.88 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-26.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2019-02-26
- MANNKIND CORP liabilities assumed for the quarter ending 2017-12-31 was -$13.00K.
- MANNKIND CORP liabilities assumed for the quarter ending 2012-06-30 was $1.00K.
- MANNKIND CORP liabilities assumed for the quarter ending 2012-03-31 was $7.63M.
- MANNKIND CORP liabilities assumed for fiscal 2017 was $1.88M.
| Period end | Liabilities Assumed | Liabilities Assumed 3 month | Liabilities Assumed 6 month | Liabilities Assumed 9 month | Liabilities Assumed 12 month | Liabilities Assumed 253 month | Liabilities Assumed 256 month |
|---|---|---|---|---|---|---|---|
| 2017-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $1.88M 10-K · filed 2019-02-26 | |||||
| 2017-09-30 | $1.89M 10-Q · filed 2018-11-01 | ||||||
| 2017-09-29 | $1.90M 10-K · filed 2018-02-27 | ||||||
| 2012-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $7.63M 10-Q · filed 2012-08-09 | $7.63M 10-Q · filed 2012-08-09 | ||||
| 2012-03-31 | $7.63M 10-Q · filed 2012-05-10 | $7.63M 10-Q · filed 2012-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |